reason report
manag mtg reinforc view underappreci sale
bottom line recent host manag meet bax
cfo jay saccaro head ir clare trachtman focu
major meet center medic deliveri perform
capit deploy innov
respect margin expans perspect follow meet
feel confid bax oper margin
expans stori incred well-vet street
well-posit exit lrp long-rang plan
near top-lin growth organ ahead overal med-tech
market mid-single-digit rang possibl even faster
growth overal via like acquisit remind bax lrp
sale compound-annual-growth-rate time-frame oper
margin ramp
immedi post-spin overal key takeaway
meet includ like acquisit
next two year signific investor pressur put
ever-grow balanc sheet work also seemingli reinvigor
bd busi develop team that produc slew new
creativ idea still exercis rigor around cfo saccaro
disciplin approach despit surpris weak
reiter medic deliveri total sale
nutrit total sale busi fundament intact
issu impact truli transient natur think also
notabl even suffer unexpect weak nearli
busi manag deliv oper sale growth
high end compani guidanc rang quarter
highlight effect compani divers busi model
post-spin renew focu innov continu ramp
new product spend final begin bear fruit new product
launch key acceler sale growth profil ultim
achiev above-market growth
reiter op pt next month believ share
trade rang dcf valuat deriv
base case upsid scenario supplement
price target arriv via ev/fcf ev/ ebitda analys
estim price-to-earnings perspect valuat appli
multipl ep estim assum
multipl expans current level pe ep
support consist beat rais quarter
estim continu move higher
medic suppli devic
pt deriv rang
dcf valuat deriv
base case upsid scenario
supplement ev/fcf ev/
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu mm ep includ stock compens expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate share outperform price target ten consecut beat
rais ep quarter sinc spin oper margin alreadi track ahead manag
current long-rang plan increasingli strong free cash flow gener believ post-
spin new turnaround stori still room signific upsid believ
increment margin upsid potenti alreadi price believ magnitud sale growth
reacceler potenti free cash flow gener still underappreci level
increasingli becom strong free cash flow gener stori free cash flow
target vs potenti upsid free cash flow
view increas financi flexibl invest busi drive even faster
sale growth acceler invest inorgan outsid opportun supplement
top- bottom-lin growth
given compani solid execut to-dat steadi stream upcom new product launch
addit clari fill gener inject busi increasingli confid
continu drive upsid recent updat long-term growth margin target
believ margin expans stori alreadi least partli price stock
manag current guid oper margin
see room upsid margin ramp believ major upsid
alreadi price share level
sale perspect also see potenti upsid current top-lin growth target
compound-annual-growth-rate time-frame driven new product launch geograph
expans someth feel underappreci street pipelin biggest
driver sale growth acceler next five year expect launch
new product new product expect make total sale
ramp expect signific growth pd periton dialysi gener inject
biosurgeri core growth contributor drive top line grow solid mid-
singl digit higher
overal find bax margin expans stori compel believ investor
underappreci bax sale growth reacceler stori also compani cash-
gener capabl believ ebitda repres relev
measur valu compani vs price earn combin
discount cash flow analysi ev/ebitda ev/fcf arriv price
manag meet reinforc view
recent host manag meet bax cfo jay saccaro head ir clare
trachtman focu major meet center medic deliveri
perform capit deploy innov respect
margin expans perspect follow meet feel confid
bax oper margin expans stori incred well-vet
street sale growth acceler stori remain underappreci us well-
posit exit lrp long-rang plan near top-lin growth
organ ahead overal med-tech market mid-single-digit rang possibl
even faster growth overal via like acquisit remind bax lrp sale
compound-annual-growth-rate time-frame oper margin ramp
immedi post-spin overal key takeaway
meet includ like acquisit next two year
signific investor pressur put ever-grow balanc sheet work also seemingli
reinvigor bd busi develop team that produc slew new creativ idea
still exercis rigor around cfo saccaro disciplin approach despit
surpris weak reiter medic deliveri total sale
nutrit total sale busi fundament intact issu
impact truli transient natur think also notabl even suffer
unexpect weak nearli busi manag deliv oper sale
growth high end compani guidanc rang quarter highlight
effect compani divers busi model post-spin renew focu
innov continu ramp new product spend final begin bear fruit new
product launch key acceler sale growth profil ultim achiev above-
 activ like acceler year
zero net debt guid free cash flow gener saccaro
acknowledg balanc sheet bit lazi saccaro emphas dividend
share repurchas key area focu also note remain top prioriti
feel us quit frankli becom increasingli higher prioriti even vs meet
manag month ago opportun lever saccaro believ
probabl someth order total capac believ manag
like evalu potenti next year vs last year primarili
view cfo saccaro level sophist within bd
increas significantli said saccaro disciplin approach hasnt chang
focu address market weight averag growth
categori leadership clear pathway get econom profil better
bax clear path improv bax year seem
primari hurdl saccaro note walk away deal last year
saccaro accret enough justifi acquisit also
emphas pressur deal fall short metric deploy
notabl recent hire new head bd work ceo almeida
covidien number deal new bd head saccaro note he pleas
sophist idea rigor theyr analyz also
reiter someth he said past prefer tuck-in vs large-scal deal given
favor econom time acknowledg wont deploy enough
capit tuck-in
miss medic deliveri key topic discuss meet
much-smal nutrit busi left meet significantli comfort
fact medic deliveri fundament much intact reiter
sale growth guidanc busi lrp ahead market
seem pretti signific confus around realli drove
medic deliveri less nutrit under-perform quarter feel
much confid issu truli transient allow
busi return growth back half year issu impact medic
deliveri drove organ sale declin includ lvp large-volum
parenter though brought suppli mexico see growth
manag note convers new bed ramp slower expect
convert bed seem occur vs saccaro also
suggest perhap greater flu effect previous assum
svp small-volum parenter suffer tight suppli issu post-hurrican maria
custom allocation-onli key product mini-bag yet back
distributor channel within nutrit suffer post-hurrican suppli issu
impact busi custom simpli slower ramp back expect
reason cite meet give us confid return medic
deliveri busi back growth make compani oper growth guidanc
within lvp bax primari focu resign group purchas organ gpo
integr deliveri network idn purchas network physician provid
extens beyond two year new suppli come mexico order
derisk busi longer term also recent sign larg oem custom
lvp supplement growth
within svp alloc septemb continu work
get mini-bag distributor channel product back
channel believ compani well-posit recaptur custom
whove forc find altern particularli given advantag need
reconstitut pharmaci need done competit product
abil reduc medic error
ask lesson learn medic deliveri under-perform
note ensur suppli chain consist hospit custom get use specif product
realloc product manufactur site know import
maintain consist saccaro note manag take look
improv visibl forecast within busi
renew focu innov set acceler sale growth profil
basic new product launch time-frame
acceler pace innov manag reiter view new product
contribut sale lot product launch next two
year saccaro trachtman note pipelin consist moonshot
rather repres iterations/evolut base technolog exist today relat
 product saccaro note still much cost devot product
support/infrastructur continu drive cost-sav via move lower-cost region
outsourc budget overal expect remain unchang allow
much higher percentag spend go toward new product develop product
discuss includ kaguya periton dialysi pd japan penetr
despit fact reimburs favor kaguya address key barrier
pd adopt japan specif automat setup reduc risk infect periton
prismax launch acut therapi launch europ set launch
late market expand crrt continu renal replac
therapi significantli reduc burden therapi spectrum iq
commun infus pump system auto-program featur launch
 enabl upgrad exist custom also captur point new
custom market share per year within overal doubl number
molecul next two year also expand geograph
next month believ share trade rang
dcf valuat deriv base case upsid scenario
supplement ev/fcf ev/ebitda analys ev/ebitda perspect
valuat right line group includ
ew estim
risk includ failur execut margin expans initi new product launch delay
possibl acquisit either dilut perceiv further baxter growth goal
could pressur stock
dollar million except asp
good sold
research develop expens
pre-tax incom continu oper
sg sale
 sale
oper expens sale
compani report leerink partner estim
